Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990269 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
A Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by ADARx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 17
- Study locations
NCT06990269 is a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration that is actively recruiting participants, run by ADARx Pharmaceuticals. The registered enrollment target is 240 participants, above the 166-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (45% higher). The trial reports 17 study locations across 9 states.
The verdict
NCT06990269, a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, is actively recruiting participants, sponsored by ADARx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 17
- Study locations
Study Summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ADX-038
Study Locations (17)
Texas
- ADARx Clinical Site - McAllen
- ADARx Clinical Site - Round Rock
- ADARx Clinical Site - San Antonio
- ADARx Clinical Site - The Woodlands
California
- ADARx Clinical Site - Beverly Hills
- ADARx Clinical Site - Huntington Beach
- ADARx Clinical Site - Poway
Arizona
- ADARx Clinical Site - Gilbert
- ADARx Clinical Site - Phoenix
New South Wales
- ADARx Clinical Site - Albury
- ADARx Clinical Site - Parramatta
Ontario
- ADARx Clinical Site - Ottawa
- ADARx Clinical Site - Toronto
Florida
- ADARx Clinical Site - Orlando
Maryland
- ADARx Clinical Site - Hagerstown
Pennsylvania
- ADARx Clinical Site - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06990269
The ClinicalTrials.gov registry entry for NCT06990269 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 166-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (45% higher). The listed sponsor is ADARx Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy Secondary to Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06990269 reports 17 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06990269 about?
NCT06990269 is a clinical study titled "Phase 2 Study of ADX-038 in Participants With Geographic Atrophy". Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
What is the current status of trial NCT06990269?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-11-10. Estimated completion is 2027-12.
What conditions does trial NCT06990269 study?
This clinical trial studies the following conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration.
What interventions are being tested in trial NCT06990269?
The interventions under investigation include: Placebo (DRUG), ADX-038 (DRUG).
Who is sponsoring clinical trial NCT06990269?
This trial is sponsored by ADARx Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990269 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING · Phase 2
-
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
RECRUITING · Phase 1
-
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.